These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 15257503)

  • 1. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 2. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-TNF revolution in ankylosing spondylitis: patients with severe disease now have access to promising new drugs.
    Schachna L
    Med J Aust; 2004 Nov; 181(10):529-30. PubMed ID: 15540959
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor necrosis factor blockers and reactivation of latent tuberculosis.
    Keane J
    Clin Infect Dis; 2004 Aug; 39(3):300-2. PubMed ID: 15306994
    [No Abstract]   [Full Text] [Related]  

  • 6. TNF-alpha antagonists: pulmonary legionellosis.
    Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.
    Savastano M; Marioni G; Giacomelli L; Ramonda R; Ferraro SM; Punzi L
    B-ENT; 2010; 6(3):183-8. PubMed ID: 21090160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological treatment of ankylosing spondylitis].
    Freiesleben S; Schou M
    Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.
    Gómez-Puerta JA; Sanmartí R; Rodríguez-Cros JR; Cañete JD
    Ann Rheum Dis; 2004 Jul; 63(7):896. PubMed ID: 15194598
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
    Lozeron P; Denier C; Lacroix C; Adams D
    Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 17. [TNF-alpha inhibitors].
    Fain O
    Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
    [No Abstract]   [Full Text] [Related]  

  • 18. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract]   [Full Text] [Related]  

  • 19. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.